BookFred Saad, Mario A. Eisenberger, editors.
Summary: This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence-based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.
Contents:
Introduction
Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities
Evolution of Clinical States and the Castration Resistant Clinical Paradigm
Molecular Mechanisms of Prostate Cancer Progression after Castration
New Imaging Modalities
Androgen Receptor Biology in Castration Resistant Prostate Cancer
The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer
Approaches Targeting Androgen Synthesis (CYP 17 inhibitors)
Cytotoxic Chemotherapy (Taxanes and Taxane Combinations)
The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer
Bone Targeted Therapy: Rationale and Current Status
Radium-223 and Other Radiopharmaceuticals in Prostate Cancer
Introduction
Phase I/II targeted treatments
Defining Clinical Endpoints in Castration-resistant Prostate Cancer
Angiogenesis Inhibition in Castration Resistant Prostate Cancer
Co-targeting Adaptive Survival Pathways
Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer
PARP Inhibitors
Targeting C-Met/VEGF in Castration Resistant Prostate Cancer
Epigenetics in Castration Resistant Prostate Cancer
Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype
Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management
Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.